SAN FRANCISCO--(BUSINESS WIRE)--Xaira Therapeutics launched today on a mission to help re-engineer the way we discover and develop medicines through the end-to-end application of emerging AI technologies. A joint incubation by ARCH Venture Partners and Foresite Labs, Xaira launched with more than $1 billion of committed capital from lead investors ARCH Venture Partners and Foresite Capital, joined by F-Prime, NEA, Sequoia Capital, Lux Capital, Lightspeed Venture Partners, Menlo Ventures, Two Sigma Ventures, the Parker Institute for Cancer Immunotherapy (PICI), Byers Capital, Rsquared, and SV Angel, among others..

旧金山--（商业新闻短讯）--Xaira Therapeutics今天启动了一项使命，通过新兴人工智能技术的端到端应用，帮助我们重新设计发现和开发药物的方式。作为ARCH Venture Partners和Foresite Labs的联合孵化，Xaira从主要投资者ARCH Venture Partners和Foresite capital那里获得了超过10亿美元的承诺资本，F-Prime、NEA、红杉资本、Lux capital、Lightspeed Venture Partners、Menlo Ventures、Two Sigma Ventures、Parker Institute for Cancer Immunotherapy（PICI）、Byers capital、Rsquared和SV Angel等加入了该项目。

Xaira brings together three core elements: advanced machine learning research, expansive data generation to power new models, and robust therapeutic product development. With leading talent and capabilities in each area, Xaira is building a platform for drug discovery and development that will advance multiple drug programs and unlock biological understanding to inform future discovery..

Xaira汇集了三个核心要素：先进的机器学习研究，扩展数据生成以支持新模型，以及强大的治疗产品开发。凭借在各个领域的领先人才和能力，Xaira正在构建一个药物发现和开发平台，该平台将推进多种药物计划，并解锁生物学理解，为未来的发现提供信息。

Xaira is building significant AI research capabilities spanning fundamental computational methods development and their application to biological discovery, the design of drug-like matter, and clinical development. Xaira was co-founded by Dr. David Baker, Professor of Biochemistry and Director of the Institute for Protein Design at the University of Washington School of Medicine.

Xaira正在建立重要的人工智能研究能力，涵盖基本的计算方法开发及其在生物发现，药物样物质设计和临床开发中的应用。Xaira由华盛顿大学医学院生物化学教授兼蛋白质设计研究所所长DavidBaker博士共同创立。

The company now employs a group of researchers who developed the leading models for protein and antibody design, RFdiffusion and RFantibody, while in Dr. Baker’s lab. Xaira’s broader team will advance these models and develop new methods that can connect the world of biological targets and engineered molecules to the human experience of disease..

该公司目前雇用了一批研究人员，他们开发了蛋白质和抗体设计，RFdiffusion和RFantibody的领先模型，而在贝克博士的实验室中，Xaira的更广泛团队将推进这些模型，并开发新方法，将生物靶点和工程分子的世界与人类疾病的体验联系起来。

Xaira’s advances in biological machine learning are underpinned by the company’s ability to generate, integrate, and learn from vast multidimensional data sets that comprehensively characterize disease-relevant biology at all scales, from molecules to people. Xaira’s internal platforms incorporate leading technologies and personnel which were spun out into Xaira at inception from Illumina’s long-standing functional genomics R&D effort.

Xaira在生物机器学习方面的进步得益于该公司能够生成，整合和学习大量多维数据集，这些数据集全面表征了从分子到人的各种尺度的疾病相关生物学。Xaira的内部平台整合了领先的技术和人员，这些技术和人员是从Illumina长期以来的功能基因组学研发工作中分离出来的。

The company has also integrated a leading proteomics group from Interline Therapeutics..

该公司还整合了Interline Therapeutics的领先蛋白质组学团队。

In the hands of an experienced team of drug developers, Xaira’s platform forms the basis of a robust therapeutic product development capability across multiple modalities. Its design capabilities, applied to previously difficult to drug targets, are the foundation for a pipeline of differentiated therapeutics.

在经验丰富的药物开发团队的手中，Xaira的平台形成了跨多种模式的强大治疗产品开发能力的基础。它的设计能力应用于以前难以药物靶点，是差异化治疗管道的基础。

The platform is also being built to transform every laboratory and clinical experiment into a vehicle for rich data generation. The product development process itself fuels the development of improved AI models and biological foundation models..

该平台还将用于将每个实验室和临床实验转换为生成丰富数据的工具。产品开发过程本身推动了改进的AI模型和生物基础模型的开发。

“We have reached the point where AI finally allows us to see biology in new ways, and translate those discoveries to better treatments for disease,” said Robert Nelsen, Managing Director and Co-Founder of ARCH Venture Partners. “This creates an enormous opportunity for us to rethink drug discovery entirely.

ARCH Venture Partners董事总经理兼联合创始人罗伯特·内尔森（RobertNelsen）表示：“我们已经达到了人工智能最终使我们能够以新的方式看待生物学，并将这些发现转化为更好的疾病治疗方法的程度。”“这为我们彻底反思药物发现创造了巨大的机会。

For this reason, Xaira is the largest initial funding commitment in ARCH history.”.

因此，Xaira是ARCH历史上最大的初始资金承诺。”

“Driven by growing data sets and new methods, there has been accelerating progress in artificial intelligence and its applications to medicine, biology and chemistry, including seminal work from David Baker’s lab at the Institute for Protein Design,” said Dr. Vikram Bajaj, CEO of Foresite Labs and Managing Director of Foresite Capital.

“在不断增长的数据集和新方法的推动下，人工智能及其在医学、生物学和化学中的应用取得了加速进展，包括蛋白质设计研究所DavidBaker实验室的开创性工作，”Forestite Labs首席执行官兼Forestite Capital常务董事Vikram Bajaj博士说。

“In starting Xaira, we have brought together incredible multidisciplinary talent and capabilities at the right time to reimagine our entire approach, from drug discovery to clinical development.”.

“在启动Xaira的过程中，我们在适当的时候汇集了令人难以置信的多学科人才和能力，重新构想了我们从药物发现到临床开发的整个方法。”

Xaira is led by renowned scientist Dr. Marc Tessier-Lavigne, former Chief Scientific Officer of Genentech and former President of Rockefeller and Stanford Universities. Other executives include co-founder Dr. Hetu Kamisetty, formerly of Meta and the Institute for Protein Design; Dr. Arvind Rajpal, formerly of Genentech; and Dr.

Xaira由著名科学家MarcTessierLavigne博士领导，他是基因泰克（Genentech）前首席科学官、洛克菲勒大学（Rockefeller）和斯坦福大学（Stanford University）前校长。其他高管包括联合创始人Hetu Kamisetty博士，前Meta和蛋白质设计研究所；Arvind Rajpal博士，前基因泰克公司；和博士。

Don Kirkpatrick, formerly of Interline and Genentech..

唐·柯克帕特里克（DonKirkpatrick），曾任职于Interline和Genentech。

“In my previous roles, I witnessed an earlier generation of technologies fundamentally change drug discovery, delivering new medicines that alleviate the burden of disease for many patients,” said Dr. Marc Tessier-Lavigne, CEO. “Now, witnessing how AI is impacting other industries and the considerable progress in applications of AI in biology, I believe we are poised for a revolution.

首席执行官马克·特西尔·拉维尼（MarcTessierLavigne）博士（Dr。“现在，目睹人工智能如何影响其他行业，以及人工智能在生物学中的应用取得了长足进步，我相信我们已经准备好进行一场革命。

Xaira is in a strong position to both advance fundamental AI research and translate these advances into transformative new medicines, and I am excited to have the opportunity to lead the team.”.

Xaira在推进基础人工智能研究和将这些进展转化为变革性新药方面处于有利地位，我很高兴有机会领导团队。”

The company’s board comprises eminent scientists and seasoned company builders, as well as executives from successful drug development enterprises and technology companies. “The board looks forward to supporting the team in building a transformative company under the visionary leadership of Marc Tessier-Lavigne,” said director Scott Gottlieb, former Food and Drug Administration commissioner and current NEA partner.

该公司董事会由杰出的科学家和经验丰富的公司建设者以及成功的药物开发企业和技术公司的高管组成。董事斯科特·戈特利布（ScottGottlieb）表示：“董事会期待着在马克·特西尔·拉维尼（MarcTessierLavigne）富有远见的领导下，支持团队建设一家变革性的公司。”斯科特·戈特利布是前食品和药物管理局局长，现任NEA合伙人。

“Xaira promises to be a magnet for the best talent in AI and drug development,” added director Kaye Foster, Senior Advisor, The Boston Consulting Group and former SVP, Global Human Resources, Onyx Pharmaceuticals..

波士顿咨询集团高级顾问、Onyx Pharmaceuticals全球人力资源前高级副总裁、董事Kaye Foster补充道：“Xaira有望成为人工智能和药物开发领域最优秀人才的磁铁。”

The board of directors currently includes:

董事会目前包括：

Vikram Bajaj, Ph.D, Co-Founder and CEO, Foresite Labs; Managing Director, Foresite Capital

Vikram Bajaj博士，Foresite Labs联合创始人兼首席执行官；Forestite Capital董事总经理

Carolyn Bertozzi, Ph.D., Baker Family Director of Sarafan ChEM-H; Anne T. and Robert M. Bass Professor; Professor (by courtesy) of Chemical and Systems Biology and of Radiology, Stanford University; Investigator, Howard Hughes Medical Institute; Nobel Prize (2022)

CarolynBertozzi博士，Sarafan ChEM-H贝克家族董事；Anne T.和Robert M.Bass教授；斯坦福大学化学和系统生物学及放射学教授（由其提供）；霍华德·休斯医学研究所研究员；诺贝尔奖（2022）

Kaye Foster, M.B.A., Senior Advisor, The Boston Consulting Group, and former SVP, Global Human Resources, Onyx Pharmaceuticals, former CHRO, Johnson & Johnson

Kaye Foster，工商管理硕士，波士顿咨询集团高级顾问，前高级副总裁，全球人力资源，Onyx制药，前CHRO，强生

Alex Gorsky, M.B.A., Former Chairman and CEO, Johnson & Johnson

Alex Gorsky，工商管理硕士，强生公司前董事长兼首席执行官

Scott Gottlieb, M.D., Former FDA Commissioner, Partner, NEA

Scott Gottlieb，医学博士，前FDA专员，NEA合伙人

Stephen Knight, M.D., President & Managing Partner, F-Prime

斯蒂芬·奈特（StephenKnight），医学博士，F-Prime总裁兼管理合伙人

Mathai Mammen, M.D., Ph.D., Chairman and CEO of FogPharma and Former EVP, Pharmaceuticals R&D, Johnson & Johnson

Mathai Mammen，医学博士，博士，FogPharma董事长兼首席执行官，强生制药研发前副总裁

Robert Nelsen, M.B.A., Co-Founder and Managing Director, ARCH Venture Partners

Robert Nelsen，工商管理硕士，ARCH Venture Partners联合创始人兼董事总经理

Richard Scheller, Ph.D., Chairman of R&D, BridgeBio; former Chief Scientific Officer and Head of Therapeutics at 23andMe, and the former Executive Vice President of Research and Early Development at Genentech; Lasker Award (2013)

Richard Scheller博士，BridgeBio研发主席；23andMe前首席科学官兼治疗学负责人，基因泰克前研究与早期开发执行副总裁；拉斯克奖（2013）

Marc Tessier-Lavigne, Ph.D., CEO Xaira; former President, Stanford University & Rockefeller University; former Chief Scientific Officer, Genentech

马克·泰西尔·拉维尼博士，首席执行官哈拉；斯坦福大学和洛克菲勒大学前校长；基因泰克前首席科学官

Bryan White, M.B.A. Chair, Advisory Board, the Institute for Protein Design; Co-Founder and Chief Investment Officer, Sahsen Ventures; former CIO Quadra/Quellos and Blackrock Alternative Advisors

Bryan White，蛋白质设计研究所顾问委员会MBA主席；Sahsen Ventures联合创始人兼首席投资官；前首席信息官Quadra/Quellos和贝莱德替代顾问

About Xaira Therapeutics

关于Xaira Therapeutics

Xaira Therapeutics is an integrated biotechnology company driving advances in artificial intelligence to learn the language of life and transform how we treat disease. The company seeks to rethink the drug discovery and development process from end-to-end by bringing together leading talent across three core areas: machine learning research to better understand biology, expansive data generation to power new models, and robust therapeutic product development to treat disease.

Xaira Therapeutics是一家综合性生物技术公司，推动人工智能的进步，以学习生命语言并改变我们治疗疾病的方式。该公司试图通过汇集三个核心领域的领先人才，从端到端重新思考药物发现和开发过程：机器学习研究以更好地理解生物学，扩展数据生成以支持新模型，以及强大的治疗产品开发以治疗疾病。

Xaira is headquartered in the San Francisco Bay Area..

Xaira总部位于旧金山湾区。